• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Drug Development and Drug Interactions: Advisory Committee Meetings

2011

2010

2009  no PS-CPAC meeting

2008

2007  no PS-CPAC meeting

2006

2005

  • Evidence and Process for Translation of Pharmacogenetic Information (e.g., CYP 2C9 polymorphisms) into Label Updates for Approved Products, Advisory Committee for Pharmaceutical Science- Clinical Pharmacology Subcommittee meeting November 14, 2005
    • Advisory Committee Information
      Labeling Recommendations for Drugs/Biologics and Device Related to Pharmacogenomic Data and Test  [PDF]
    • How New Insights into Pharmacogenomics Lead to Revisions of Product Labels [PPT]
    • FDA Pharmacogenetic Labels: A clinical perspective [PPT]

2004

  • Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, discussed at the FDA Advisory Committee for pharmaceutical sciences and Clinical Pharmacology Subcommittee meeting. Issues drug interaction concept paper. Rockville, MD. November 3, 2004. 

     

2003

  • CYP2B6/CYP2C8 Drug Interactions, Advisory Committee for Pharmaceutical Science- Clinical Pharmacology Subcommittee meeting, November 18, 2003, Rockville, MD. 

     

  • Huang, S, Issues and Challenges in the Evaluation and Labeling of Drug Interaction Potentials of NME, Advisory Committee for Pharmaceutical Science- Clinical Pharmacology Subcommittee meeting, April 23, 2003, Rockville, MD.